title: The double-edged sword of autoimmunity: lessons from multiple sclerosis.
abstract: The relationship between immune responses to self-antigens and autoimmune disease is unclear. In contrast to its animal model experimental autoimmune encephalomyelitis (EAE), which is driven by T cell responses to myelin antigens, the target antigen of the intrathecal immune response in multiple sclerosis (MS) has not been identified. Although the immune response in MS contributes significantly to tissue destruction, the action of immunocompetent cells within the central nervous system (CNS) may also hold therapeutic potential. Thus, treatment of MS patients with glatiramer acetate triggers a protective immune response. Here we review the immunopathogenesis of MS and some recent findings on the mechanism of glatiramer acetate (GA).
authors: Institute of Immunology, Faculty of Medicine, University of Oslo, Oslo University Hospital, Rikshospitalet, 0027 Oslo, Norway. anne.lise.hestvik@rr-research.no
authors: Anne Lise K
authors: AL
authors: Hestvik
mesh_terms: D000818:Animals; D015551:Autoimmunity; D001812:Blood-Brain Barrier; D002465:Cell Movement; D002490:Central Nervous System / Q000276:immunology; D000068717:Glatiramer Acetate; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000209:etiology / Q000276:immunology*; D010455:Peptides / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D010455:Peptides; D000068717:Glatiramer Acetate